Your browser doesn't support javascript.

Portal de Pesquisa da BVS Veterinária

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:



Adicionar mais destinatários

Enviar resultado
| |

Heterologous fibrin sealant derived from snake venom: from bench to bedside - an overview

Ferreira Jr, Rui Seabra; Barros, Luciana Curtolo de; Abbade, Luciana Patrícia Fernandes; Barraviera, Silvia Regina Catharino Sartori; Silvares, Maria Regina Cavariani; Pontes, Leticia Gomes de; Santos, Lucilene Delazari dos; Barraviera, Benedito.
J. venom. anim. toxins incl. trop. dis; 23: 21, 2017. tab, graf, ilus
Artigo em Inglês | LILACS | ID: biblio-954833


Hemostatic and adhesive agents date back to World War II, when homologous fibrin sealant came onto scene. Considering that infectious diseases can be transmitted via human blood, a new heterologous fibrin sealant was standardized in the 1990s. Its components were a serine protease (a thrombin-like enzyme) extracted from the venom of Crotalus durissus terrificus snakes and a fibrinogen-rich cryoprecipitate extracted from the blood of Bubalus bubalis buffaloes. This new bioproduct has been used as a coagulant, sealant, adhesive and recently as a candidate scaffold for mesenchymal stem cells and bone and cartilage repair. This review discusses the composition of a new heterologous fibrin sealant, and cites published articles related to its preclinical applications aiming at repairing nervous system traumas and regenerating bone marrow. Finally, we present an innovative safety trial I/II that found the product to be a safe and clinically promising candidate for treating chronic venous ulcers. A multicenter clinical trial, phase II/III, with a larger number of participants will be performed to prove the efficacy of an innovative biopharmaceutical product derived from animal venom.(AU)
Biblioteca responsável: BR68.1